A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
Latest Information Update: 15 Apr 2025
At a glance
- Drugs INR-101 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- Sponsors Yunhe Pharmaceutical (Tianjin)
Most Recent Events
- 15 Apr 2025 New trial record